Uniqure’s (QURE) Buy Rating Reaffirmed at Janney Montgomery Scott

Janney Montgomery Scott reaffirmed their buy rating on shares of Uniqure (NASDAQ:QURE) in a report released on Tuesday, TipRanks reports.

QURE has been the topic of a number of other research reports. BidaskClub upgraded Uniqure from a buy rating to a strong-buy rating in a research note on Wednesday, March 13th. Chardan Capital boosted their price objective on Uniqure from $70.00 to $100.00 and gave the stock a buy rating in a research note on Monday, March 4th. Piper Jaffray Companies assumed coverage on Uniqure in a research note on Friday, April 12th. They set an overweight rating and a $80.00 price objective on the stock. HC Wainwright restated a buy rating on shares of Uniqure in a research note on Tuesday, February 26th. Finally, Zacks Investment Research upgraded Uniqure from a hold rating to a strong-buy rating and set a $66.00 price objective on the stock in a research note on Tuesday, March 5th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Uniqure presently has an average rating of Buy and a consensus target price of $75.82.

Shares of QURE opened at $65.97 on Tuesday. The stock has a market cap of $2.83 billion, a price-to-earnings ratio of -28.19 and a beta of 0.95. Uniqure has a 12 month low of $21.98 and a 12 month high of $78.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 9.51 and a current ratio of 9.51.

Uniqure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, April 29th. The biotechnology company reported ($0.74) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.03). The company had revenue of $1.14 million for the quarter, compared to analyst estimates of $2.00 million. Uniqure had a negative return on equity of 48.90% and a negative net margin of 1,032.06%. As a group, equities research analysts predict that Uniqure will post -3.01 earnings per share for the current fiscal year.

In related news, Director Philip Astley-Sparke sold 6,000 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $63.63, for a total value of $381,780.00. Following the transaction, the director now owns 18,872 shares in the company, valued at $1,200,825.36. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Matthew C. Kapusta sold 67,376 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $63.96, for a total value of $4,309,368.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 88,922 shares of company stock worth $5,605,629. Insiders own 2.91% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the stock. Redmile Group LLC increased its holdings in Uniqure by 0.3% in the first quarter. Redmile Group LLC now owns 1,307,522 shares of the biotechnology company’s stock valued at $77,994,000 after buying an additional 4,100 shares during the last quarter. FMR LLC increased its holdings in Uniqure by 0.8% in the first quarter. FMR LLC now owns 3,688,791 shares of the biotechnology company’s stock valued at $220,036,000 after buying an additional 29,629 shares during the last quarter. BlueMountain Capital Management LLC bought a new stake in Uniqure in the first quarter valued at about $58,000. Kore Private Wealth LLC bought a new stake in Uniqure in the first quarter valued at about $30,000. Finally, Perceptive Advisors LLC increased its holdings in Uniqure by 5.0% in the first quarter. Perceptive Advisors LLC now owns 231,820 shares of the biotechnology company’s stock valued at $13,828,000 after buying an additional 11,113 shares during the last quarter. Institutional investors and hedge funds own 60.12% of the company’s stock.

About Uniqure

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Recommended Story: What is the market perform rating?

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.